Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Leukemia, Myeloid, Acute 12Sarcoma, Kaposi 5HIV Infections 5Acquired Immunodeficiency Syndrome 5Myeloproliferative Disorders 4Neoplasm Metastasis 2Myelodysplastic Syndromes 2Leukemia, Monocytic, Acute 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Burkitt Lymphoma 1Breast Neoplasms 1Breast Cancer Metastatic 1Advanced Cancer 1

Interventions

pembrolizumab 157Gemcitabine 140Capecitabine 123Paclitaxel 121Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Docetaxel 98Leucovorin 97Cisplatin 90Radiosurgery 88Irinotecan 88Carboplatin 86Cyclophosphamide 72Cetuximab 72Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Liposomes × Clear all
NCT00761644 2019-04-11

Doxil, Bevacizumab and Temsirolimus Trial

M.D. Anderson Cancer Center

Phase 1 Completed
200 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01333423 2012-06-26

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡